A SLEEP APNEA THERAPY DEVICE— for anytime and anywhere. PAP therapy has long been first-line treatment for obstructive sleep apnea (OSA). However,
long-term compliance continues to range from 30 to 70%, diminishing response to therapy.

Options for OSA treatment include oral appliances, surgery and nasal expiratory positive airway pressure (EPAP).

The Bongo Rx was recently cleared by the FDA for the treatment of mild-to-moderate OSA using EPAP. This novel device consists of a conjoined set of soft nasal EPAP valves inserted in the nares, also providing a mild degree of dilation. (Figure 1) The aim of this study was to determine the efficacy of this novel EPAP device and what that might mean for patient comfort and ease of use.